Cost-utility of first-line actinic keratosis treatments in Finland.

ABSTRACT:

Introduction

Cost-utility assessment of first-line actinic keratosis (AK) treatments for max 25 cm2 AK field.

Methods

A probabilistic, 2-year decision tree model was used to assess costs, quality-adjusted life-years (QALY), incremental cost-effectiveness ratio (ICER), cost-effectiveness efficiency frontier, cost-effectiveness acceptability frontier (CEAF), and expected value of perfect information (EVPI) of AK treatments from the Finnish health care payer perspective with 3% discounting per annum. In the model, the first-line AK treatment resulted in complete clearance (CC) or non-CC with or without local skin responses (LSR), or AK recurrence. Non-CC AK was treated with methyl aminolevulinate+photodynamic therapy (MAL+PDT), and AK recurrence was retreated with the previous

SUBMITTER: Soini EJ 

PROVIDER: S-EPMC4449383 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature